Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis.

Jones JL, Scheidt DJ, Kaushal RS, Carroll CA.

J Med Econ. 2013;16(2):213-20. doi: 10.3111/13696998.2012.744316. Epub 2012 Nov 8.

PMID:
23098539
2.

The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.

Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ.

J Med Econ. 2011;14(6):739-47. doi: 10.3111/13696998.2011.618517. Epub 2011 Sep 13.

PMID:
21913796
3.

Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.

Fraser C, Hadjimichael O, Vollmer T.

J Neurosci Nurs. 2001 Oct;33(5):231-9.

PMID:
11668881
4.

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.

BMC Neurol. 2011 Mar 30;11:40. doi: 10.1186/1471-2377-11-40.

5.

Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.

Simpson D, Noble S, Perry C.

BioDrugs. 2003;17(3):207-10. Review.

PMID:
12749757
6.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.

Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.

PMID:
20637960
7.

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.

Lage MJ, Carroll CA, Fairman KA.

J Med Econ. 2013 Sep;16(9):1146-53. doi: 10.3111/13696998.2013.823868. Epub 2013 Aug 8.

PMID:
23844620
8.

[Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].

Oreja-Guevara C, Bermejo PE, Miralles A, Gabaldón L, Aguilar MJ, Díez-Tejedor E.

Neurologia. 2009 Sep;24(7):435-8. Spanish.

PMID:
19921551
9.

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Johnson KP.

Expert Rev Neurother. 2012 Apr;12(4):371-84. doi: 10.1586/ern.12.25. Review.

PMID:
22449210
10.
11.

Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.

Qizilbash N, Mendez I, Sanchez-de la Rosa R.

Clin Ther. 2012 Jan;34(1):159-176.e5. doi: 10.1016/j.clinthera.2011.12.006. Review.

PMID:
22284996
12.

Medication adherence with disease modifying treatments for multiple sclerosis among US employees.

Kleinman NL, Beren IA, Rajagopalan K, Brook RA.

J Med Econ. 2010;13(4):633-40. doi: 10.3111/13696998.2010.527588. Epub 2010 Oct 19.

PMID:
20958113
13.

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.

Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW; GA/minocycline study investigators.

Mult Scler. 2009 Oct;15(10):1183-94. doi: 10.1177/1352458509106779. Epub 2009 Sep 23.

PMID:
19776092
14.
15.

Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.

Pardo G, Boutwell C, Conner J, Denney D, Oleen-Burkey M.

J Neurosci Nurs. 2010 Feb;42(1):40-6.

PMID:
20187348
16.

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.

Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.2165/11314900-000000000-00000.

PMID:
19731967
17.

Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data.

Caon C, Saunders C, Smrtka J, Baxter N, Shoemaker J.

J Neurosci Nurs. 2010 Oct;42(5 Suppl):S5-9. Review.

PMID:
21049828
18.
19.

Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.

Azoulay D, Vachapova V, Shihman B, Miler A, Karni A.

J Neuroimmunol. 2005 Oct;167(1-2):215-8.

PMID:
16083971

Supplemental Content

Support Center